Table 3.

Expression of PD-L1 and PD-L2 in tumors and clinical significance

CancerNo. of samplesPD-L1 (%)PD-L2 (%)Clinical associationReference
Renal cell carcinoma196663-fold increased mortality(78)
    Tumor-infiltrating lymphocytes593.6-fold increased mortality
Non–small cell lung cancer52100100None(79)
Breast cancer4450Associated with grade III, and estrogen/progesterone receptors(80)
    Tumor infiltrating lymphocytes34Associated with tumor size, grade III, Her2/neu positive status
Gastric carcinoma10242.2Associated with tumor size, invasion, metastasis, and survival(82)
Bladder urothelial carcinoma65100Associated with high recurrence and poor survival(84)
Bladder urothelial carcinoma28036.1Associated with high-grade tumor infiltrating mononuclear cells(83)
Ovarian cancer7068.6Poor prognostic factor for survival(81)
Inversely associated with intraepithelial CD8 cells
37.1None
Pancreatic cancer5138.2Associated with poor survival(85)
Inversely associated with tumor-infiltrating CD8 cells
27.5None